S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
NASDAQ:NEOG

Neogen Stock Forecast, Price & News

$39.35
-0.78 (-1.94%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$39.29
$41.00
50-Day Range
$40.13
$45.33
52-Week Range
$36.51
$48.85
Volume
273,757 shs
Average Volume
339,590 shs
Market Capitalization
$4.23 billion
P/E Ratio
67.26
Dividend Yield
N/A
Beta
0.45
30 days | 90 days | 365 days | Advanced Chart
Receive NEOG News and Ratings via Email

Sign-up to receive the latest news and ratings for Neogen and its competitors with MarketBeat's FREE daily newsletter.


Neogen logo

About Neogen

Neogen Corp. engages in the development, manufacture, and sale of products dedicated to food and animal safety. It operates through the following segments: Food Safety and Animal Safety. The Food Safety segment consists of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, drug residues, and levels of general sanitation. The Animal Safety segment includes a line of consumable products marketed to veterinarians and animal health product distributors. The company was founded on June 30, 1981 and is headquartered in Lansing, MI.

Headlines

NEOGEN Acquires Delf (UK) Ltd.
December 1, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:NEOG
CUSIP
64049110
Employees
1,764
Year Founded
1982

Sales & Book Value

Annual Sales
$468.46 million
Cash Flow
$0.67 per share
Book Value
$7.85 per share

Profitability

Net Income
$60.88 million
Pretax Margin
15.84%

Debt

Price-To-Earnings

Miscellaneous

Free Float
106,934,000
Market Cap
$4.23 billion
Optionable
Optionable

Company Calendar

Last Earnings
9/20/2021
Today
12/02/2021
Next Earnings (Estimated)
12/28/2021
Fiscal Year End
5/31/2022

Social Links


MarketRank

Overall MarketRank

1.72 out of 5 stars

Medical Sector

903rd out of 1,392 stocks

Diagnostic Substances Industry

12th out of 25 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -












Neogen (NASDAQ:NEOG) Frequently Asked Questions

How has Neogen's stock price been impacted by Coronavirus?

Neogen's stock was trading at $15.1825 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NEOG shares have increased by 159.2% and is now trading at $39.35.
View which stocks have been most impacted by COVID-19
.

When is Neogen's next earnings date?

Neogen is scheduled to release its next quarterly earnings announcement on Tuesday, December 28th 2021.
View our earnings forecast for Neogen
.

How were Neogen's earnings last quarter?

Neogen Co. (NASDAQ:NEOG) issued its quarterly earnings data on Monday, September, 20th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The business had revenue of $128.30 million for the quarter, compared to the consensus estimate of $121.20 million. Neogen had a trailing twelve-month return on equity of 7.57% and a net margin of 12.74%. The company's revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.30 earnings per share.
View Neogen's earnings history
.

When did Neogen's stock split? How did Neogen's stock split work?

Neogen shares split on Tuesday, January 2nd 2018. The 4-3 split was announced on Friday, December 8th 2017. The newly created shares were distributed to shareholders after the closing bell on Friday, December 29th 2017. An investor that had 100 shares of Neogen stock prior to the split would have 133 shares after the split.

Who are Neogen's key executives?

Neogen's management team includes the following people:
  • John E. Adent, President, CEO & Director
  • Steven James Quinlan, Chief Financial Officer & Vice President (LinkedIn Profile)
  • Joseph M. Madden, Vice President-Scientific Affairs
  • Robert Donofrio, Vice President-Research & Development
  • Julie A. Mann, Chief Human Resources Officer & Vice President

What is John Adent's approval rating as Neogen's CEO?

31 employees have rated Neogen CEO John Adent on Glassdoor.com. John Adent has an approval rating of 56% among Neogen's employees. This puts John Adent in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neogen investors own include NVIDIA (NVDA), NIKE (NKE), Pfizer (PFE), AT&T (T), AbbVie (ABBV), Boeing (BA), JPMorgan Chase & Co. (JPM), W. P. Carey (WPC), Advanced Micro Devices (AMD) and Costco Wholesale (COST).

What is Neogen's stock symbol?

Neogen trades on the NASDAQ under the ticker symbol "NEOG."

Who are Neogen's major shareholders?

Neogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.84%), Wasatch Advisors Inc. (6.67%), Conestoga Capital Advisors LLC (3.52%), Neuberger Berman Group LLC (1.99%), Geode Capital Management LLC (1.83%) and Dimensional Fund Advisors LP (1.56%). Company insiders that own Neogen stock include Bruce Papesh, James L Herbert, James P Tobin, Jason Warren Lilly, John Edward Adent, Steven J Quinlan, Terri A Morrical, Thomas H Reed and William T Boehm.
View institutional ownership trends for Neogen
.

Which institutional investors are selling Neogen stock?

NEOG stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., New York State Common Retirement Fund, Morgan Stanley, Goldman Sachs Group Inc., Bamco Inc. NY, Beacon Investment Advisory Services Inc., Neuberger Berman Group LLC, and Van ECK Associates Corp. Company insiders that have sold Neogen company stock in the last year include Bruce Papesh, Jason Warren Lilly, John Edward Adent, Steven J Quinlan, Terri A Morrical, and William T Boehm.
View insider buying and selling activity for Neogen
or view top insider-selling stocks.

Which institutional investors are buying Neogen stock?

NEOG stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Arrowstreet Capital Limited Partnership, Allianz Asset Management GmbH, Tudor Investment Corp Et Al, Dimensional Fund Advisors LP, AlphaCrest Capital Management LLC, and Aviva PLC. Company insiders that have bought Neogen stock in the last two years include James P Tobin, and John Edward Adent.
View insider buying and selling activity for Neogen
or or view top insider-buying stocks.

How do I buy shares of Neogen?

Shares of NEOG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neogen's stock price today?

One share of NEOG stock can currently be purchased for approximately $39.35.

How much money does Neogen make?

Neogen has a market capitalization of $4.23 billion and generates $468.46 million in revenue each year. The company earns $60.88 million in net income (profit) each year or $0.5850 on an earnings per share basis.

How many employees does Neogen have?

Neogen employs 1,764 workers across the globe.

When was Neogen founded?

Neogen was founded in 1982.

What is Neogen's official website?

The official website for Neogen is www.neogen.com.

Where are Neogen's headquarters?

Neogen is headquartered at 620 LESHER PLACE, LANSING MI, 48912.

How can I contact Neogen?

Neogen's mailing address is 620 LESHER PLACE, LANSING MI, 48912. The company can be reached via phone at (517) 372-9200, via email at [email protected], or via fax at 517-372-2006.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.